Identification of a panel of ten cell surface protein antigens associated with immunotargeting of leukemias and lymphomas by peripheral blood γδ t cells

Haematologica

Volumn 95, Issue 8, 2010, Pages 1397-1404

  Gomes, Anita Q ^a,b,c   Correia, Daniel V ^a,b   Grosso, Ana R ^a   Lança, Telma ^a   Ferreira, Cristina ^d   Lacerda, João F ^d   Barata, João T ^a   da Silva, Maria Gomes ^e   Silva Santos, Bruno ^a,b  

^a UNIVERSITY OF LISBON   (Portugal)

^b INSTITUTO GULBENKIAN DE CIÊNCIA   (Portugal)

^c INSTITUTO POLITÉCNICO DE LISBOA   (Portugal)

^d HOSPITAL DE SANTA MARIA   (Portugal)

^e Instituto Portugues de Oncologia de Lisboa   (Portugal)

Author keywords

Biomarkers; Hematopoietic tumors; Lymphoma cell lines; V 9v 2 t lymphocytes

Indexed keywords

ALPHA6 INTEGRIN; C TYPE LECTIN 2 D; CELL SURFACE PROTEIN; COMPLEMENTARY DNA; INTERFERON INDUCED TRANSMEMBRANE PROTEIN 1; L SELECTIN; LECTIN; MEMBRANE ANTIGEN; NEUROPILIN 2; POLYCYSTIC KIDNEY DISEASE 2 PROTEIN; POLYCYSTIN 2; POTASSIUM CHANNEL; POTASSIUM CHANNEL K12; RNA; SIGNALING LYMPHOCYTE ACTIVATION MOLECULE 1; TRANSFERRIN RECEPTOR 2; UL16 BINDING PROTEIN; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIGEN DETECTION; ARTICLE; BIOINFORMATICS; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; CYTOLYSIS; DNA MICROARRAY; FOLLICULAR LYMPHOMA; GAMMA DELTA T LYMPHOCYTE; GENE EXPRESSION PROFILING; GENOME ANALYSIS; HEMATOPOIETIC SYSTEM TUMOR; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LYMPHOMA CELL LINE; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PROGNOSIS; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE SUBPOPULATION;

ANTIGENS, DIFFERENTIATION; ANTIGENS, SURFACE; CELL LINE, TUMOR; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION TO DISEASE; GPI-LINKED PROTEINS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; JURKAT CELLS; LEUKEMIA; LEUKOCYTES, MONONUCLEAR; LYMPHOMA; MEMBRANE PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; RECEPTORS, TRANSFERRIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES;

EID: 77956032245     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.020602     Document Type: Article

References (35)

1. Kabelitz D, Wesch D, He W. Perspectives of gammadelta T cells in tumor immunology. Cancer Res. 2007;67(1):5-8.
2. Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, Filler R, et al. Regulation of cutaneous malignancy by gammadelta T cells. Science. 2001;294 (5542):605-609.
3. Gao Y, Yang W, Pan M, Scully E, Girardi M, Augenlicht LH, et al. Gamma delta T cells provide an early source of interferon gamma in tumor immunity. J Exp Med. 2003;198(3):433-442.
4. Liu Z, Eltoum IE, Guo B, Beck BH, Cloud GA, Lopez RD. Protective immunosurveillance and therapeutic antitumor activity of gammadelta T cells demonstrated in a mouse model of prostate cancer. J Immunol. 2008;180(9):6044-6053.
5. Street SE, Hayakawa Y, Zhan Y, Lew AM, MacGregor D, Jamieson AM, et al. Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and gammadelta T cells. J Exp Med. 2004;199(6): 879-884.
6. Morita CT, Jin C, Sarikonda G, Wang H. Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vgamma2Vdelta2 T cells: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens. Immunol Rev. 2007;215:59-76.
7. Correia DV, d'Orey F, Cardoso BA, Lanca T, Grosso AR, deBarros A, et al. Highly active microbial phosphoantigen induces rapid yet sustained MEK/Erk- and PI-3K/Aktmediated signal transduction in anti-tumor human gammadelta T-cells. PLoS One. 2009;4(5):e5657.
8. Sicard H, Al Saati T, Delsol G, Fournie JJ. Synthetic phosphoantigens enhance human Vgamma9Vdelta2 T lymphocytes killing of non-Hodgkin's B lymphoma. Mol Med. 2001;7(10):711-722.
9. Kunzmann V, Wilhelm M. Anti-lymphoma effect of gammadelta T cells. Leuk Lymphoma. 2005;46(5):671-680.
10. Tokuyama H, Hagi T, Mattarollo SR, Morley J, Wang Q, Fai-So H, et al. V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs-rituximab and trastuzumab. Int J Cancer. 2008;122(11): 2526-2534.
11. Dieli F, Vermijlen D, Fulfaro F, Caccamo N, Meraviglia S, Cicero G, et al. Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res. 2007;67(15):7450-7457.
12. Kobayashi H, Tanaka Y, Yagi J, Osaka Y, Nakazawa H, Uchiyama T, et al. Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol Immunother. 2007;56(4):469-476.
13. Bennouna J, Bompas E, Neidhardt EM, Rolland F, Philip I, Galea C, et al. Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother. 2008;57(11):1599-1609.
14. Wilhelm M, Kunzmann V, Eckstein S, Reimer P, Weissinger F, Ruediger T, et al. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood. 2003;102(1):200-206.
15. Gertner-Dardenne J, Bonnafous C, Bezombes C, Capietto AH, Scaglione V, Ingoure S, et al. Bromohydrin pyrophosphate enhances antibody-dependent cellmediated cytotoxicity induced by therapeutic antibodies. Blood. 2009;113(20): 4875-4884.
16. Abe Y, Muto M, Nieda M, Nakagawa Y, Nicol A, Kaneko T, et al. Clinical and immunological evaluation of zoledronateactivated Vgamma9gammadelta T-cellbased immunotherapy for patients with multiple myeloma. Exp Hematol. 2009; 37(8):956-968.
17. Team RDC. R: A Language and Environment for Statistical Computing. In: Computing RFfS, ed. Vienna, Austria, 2009.
18. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5(10):R80.
19. Gautier L, Cope L, Bolstad BM, Irizarry RA. affy-analysis of Affymetrix GeneChip datan at the probe level. Bioinformatics. 2004;20(3):307-315.
20. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3:Article3.
21. Smyth GK. Limma: linear models for microarray data. In: R. Gentleman and V. Carey and S. Dudoit and R. Irizarry WH, ed. Bioinformatics and Computational Biology Solutions using R and Bioconductor. New York: Springer, 2005: 397-420.
22. Benjamini YH, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society Series B. 1995;57:289-300.
23. Ringner M. What is principal component analysis? Nat Biotechnol. 2008;26(3):303-304.
24. Li J, Herold MJ, Kimmel B, Muller I, Rincon-Orozco B, Kunzmann V, et al. Reduced expression of the mevalonate pathway enzyme farnesyl pyrophosphate synthase unveils recognition of tumor cells by Vgamma9Vdelta2 T cells. J Immunol. 2009;182(12):8118-8124.
25. Vantourout P, Mookerjee-Basu J, Rolland C, Pont F, Martin H, Davrinche C, et al. Specific requirements for Vgamma9Vdelta2 T cell stimulation by a natural adenylated phosphoantigen. J Immunol. 2009;183(6): 3848-3857.
26. Scotet E, Martinez LO, Grant E, Barbaras R, Jeno P, Guiraud M, et al. Tumor recognition following Vgamma9Vdelta2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I. Immunity. 2005;22(1):71-80.
27. Kong Y, Cao W, Xi X, Ma C, Cui L, He W. The NKG2D ligand ULBP4 binds to TCRgamma9/delta2 and induces cytotoxicity to tumor cells through both TCRgammadelta and NKG2D. Blood. 2009;114(2):310-317.
28. Sole X, Bonifaci N, Lopez-Bigas N, Berenguer A, Hernandez P, Reina O, et al. Biological convergence of cancer signatures. PLoS One. 2009;4(2):e4544.
29. Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol. 2003;3(10):781-790.
30. Gomes AQ, Correia DV, Silva-Santos B. Non-classical major histocompatibility complex proteins as determinants of tumour immunosurveillance. EMBO Rep. 2007;8(11):1024-1030.
31. Guerra N, Tan YX, Joncker NT, Choy A, Gallardo F, Xiong N, et al. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity. 2008;28(4):571-580.
32. Strid J, Roberts SJ, Filler RB, Lewis JM, Kwong BY, Schpero W, et al. Acute upregulation of an NKG2D ligand promotes rapid reorganization of a local immune compartment with pleiotropic effects on carcinogenesis. Nat Immunol. 2008;9(2):146-154.
33. Yang Y, Lee JH, Kim KY, Song HK, Kim JK, Yoon SR, et al. The interferon-inducible 9-27 gene modulates the susceptibility to natural killer cells and the invasiveness of gastric cancer cells. Cancer Lett. 2005; 221(2): 191-200.
34. Roth P, Mittelbronn M, Wick W, Meyermann R, Tatagiba M, Weller M. Malignant glioma cells counteract antitumor immune responses through expression of lectin-like transcript-1. Cancer Res. 2007;67(8):3540-3544.
35. Pellet-Many C, Frankel P, Jia H, Zachary I. Neuropilins: structure, function and role in disease. Biochem J. 2008;411(2):211-226.